Peptides · Peptide comparison
Pancragen vs Xenin-25
Tetrapeptide bioregulator (Lys-Glu-Asp-Trp) that binds ACCT sequences in pancreatic gene promoters with 3-fold greater affinity than related peptides, stimulates beta-cell differentiation through Pdx1/Pax6/NGN3 transcription factor activation, and corrects impaired glucose tolerance in primates more physiologically than glimepiride
The Natural Incretin Helper Peptide That Enhances Glucose Control and Insulin Response
- Metabolic
- Metabolic
At a glance
Quick comparison
Efficacy
Benefit ratings
Blood Sugar Balance
Pancreas Protection
Metabolic Aging Support
Glucose Control & Insulin Response
Metabolic Synergy
Natural Physiological Action
Technical data
Compound specifications
Pancragen
- Molecular formula
- C26H36N6O9
- Molecular weight
- 576.6 g/mol
- Half-life
- Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic modifications to pancreatic gene expression (primate studies showed partial effects 3 weeks post-treatment); metabolized to constituent amino acids
- Bioavailability
- Demonstrated efficacy with both oral (Pankragen-Forte capsules) and intramuscular routes; penetrates cell membranes and nuclear membranes to reach DNA promoter regions; oral bioavailability sufficient for clinical effects at 500 mcg doses
- CAS number
- Not definitively assigned
Xenin-25
- Molecular formula
- C139H224N38O32S
- Molecular weight
- 2971.6 g/mol
- Half-life
- 10-15 minutes (IV administration, subject to variation)
- Bioavailability
- IV: ~100%; Subcutaneous: Research-dependent; Oral: Limited due to peptide nature (active research)
- CAS number
- Not available
Protocols
Dosing compared
Pancragen
Oral
- 500 mcgTwice daily (morning and evening) · 4-week courseDocumented oral dose for the Pankragen-Forte capsule: 500 mcg twice daily for 4 weeks in elderly patients with a prediabetic state [3]. The intramuscular route appears only in animal studies with no published human dose, so it is not listed here.
Xenin-25
Intravenous infusion
- 4 pmol/kg/min (after a brief higher loading ramp of 10.8→7.7→5.6 pmol/kg/min over the first 10 min)Continuous infusion · Up to ~4 hours (during glucose clamp)Human IV infusion dose used to amplify GIP-mediated insulin secretion during a hyperglycemic clamp [5]. Research use only.
Applications
Best suited for
Pancragen
- Supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies
- Pancragen is particularly well-suited for individuals focused on supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
- Pancragen is particularly well-suited for individuals focused on geroprotective pancreatic support to maintain beta-cell differentiation and insulin production. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Comprehensive Khavinson bioregulator protocols targeting metabolic aging
- Pancragen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting metabolic aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance
- Pancragen is particularly well-suited for individuals focused on adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Xenin-25
- Supporting healthy glucose metabolism
- Xenin-25 is particularly well-suited for individuals focused on supporting healthy glucose metabolism. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Enhancing insulin response efficiency
- Xenin-25 is particularly well-suited for individuals focused on enhancing insulin response efficiency. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Research into metabolic disorder treatment
- Xenin-25 is particularly well-suited for individuals focused on research into metabolic disorder treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
Pancragen
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Minor digestive changes
Uncommon
- Mild hypoglycemia
Serious
- No documented serious adverse effects
Xenin-25
Common
- Gastrointestinal Discomfort
- Nausea
- Headache
Uncommon
- Injection Site Reactions
- Mild Fatigue
Serious
- Hypoglycemia Risk
Research status
Safety & evidence
Pancragen
- Evidence level
- Limited human trials
- FDA status
- Research compound
- Safety overview
- Pancragen shows favorable safety profile in preclinical toxicology studies with no serious adverse events at therapeutic doses. As a multi-peptide complex derived from pancreatic tissue, potential allergenicity risk exists in porcine-sensitive individuals. Gastrointestinal tolerance is excellent when taken orally. Limited human clinical data; primarily used in clinical practice in Central/Eastern Europe with reported safety in observational studies.
Contraindications
- Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, tryptophan)
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Active hypoglycemia or insulin-secreting tumors (insulinoma) — Pancragen's beta-cell stimulating effects may exacerbate hypoglycemia
- Concurrent use of sulfonylureas without medical supervision — potential for additive hypoglycemic effects
Xenin-25
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Xenin-25 is a 25-amino acid natural gut peptide discovered in 1992 with moderate evidence from Phase 1-2 human clinical trials. The peptide has been extensively studied in metabolic research for over 30 years. Safety profile shows good tolerability in research settings with mild, transient gastrointestinal effects being the most common. Critical limitation: Xenin-25 has NOT completed Phase 3 clinical trials and is not FDA-approved for clinical use. No serious adverse effects have been reported in research studies, but hypoglycemia risk requires careful monitoring when combined with insulin or other glucose-lowering agents. Individual responses to Xenin-25 are generally mild gastrointestinal discomfort, nausea, or headache in the first few days—these typically resolve with continued use. The peptide's glucose-dependent mechanism makes hypoglycemia unlikely when used alone, but additive effects with other agents require medical supervision.
Contraindications
- Pregnancy and breastfeeding
- Severe kidney or liver disease
Decision guide
Which is right for you?
Pancragen
Choose Pancragen if…
- Supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies
- Geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
- Comprehensive Khavinson bioregulator protocols targeting metabolic aging
- Adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance
Xenin-25
Choose Xenin-25 if…
- Supporting healthy glucose metabolism
- Enhancing insulin response efficiency
- Research into metabolic disorder treatment